Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00204776 · ClinicalTrials.gov registry record · Phase 2
XELOX for Metastatic Breast Cancer
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00204776 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 37 participants.
The verdict
NCT00204776, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
Both capecitabine and oxaliplatin have single agent activity in breast cancer. The combination has improved activity in other solid tumors. This study seeks to assess the activity of the combination in breast cancer.
Interventions
- DRUG Capecitabine and Oxaliplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00204776
The ClinicalTrials.gov registry entry for NCT00204776 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Capecitabine and Oxaliplatin is the first listed.
NCT00204776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00204776 about?
NCT00204776 is a clinical study titled "XELOX for Metastatic Breast Cancer". Both capecitabine and oxaliplatin have single agent activity in breast cancer. The combination has improved activity in other solid tumors. This study seeks to assess the activity of the combination in breast cancer.
What is the current status of trial NCT00204776?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2005-03. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00204776?
The interventions under investigation include: Capecitabine and Oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT00204776?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.